Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease - Wikidata - awgldk - TriplyDB

Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease

Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease

http://www.wikidata.org/entity/Q35932749

about

Clinical development of gene therapy: results and lessons from recent successes New approaches to the treatment of orphan genetic disorders: Mitigating molecular pathologies using chemicals Gene therapy for lower urinary tract dysfunction Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders Synthetic biology and therapeutic strategies for the degenerating brain: Synthetic biology approaches can transform classical cell and gene therapies, to provide new cures for neurodegenerative diseases Parkinson's disease gene therapy: success by design meets failure by efficacy Gene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced delivery Treating Parkinson's disease in the 21st century: can stem cell transplantation compete?Adeno-associated virus-mediated cancer gene therapy: current status Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE.Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I Clinical applications involving CNS gene transfer.Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIB.Basic FGF or VEGF gene therapy corrects insufficiency in the intrinsic healing capacity of tendons.Focusing brain therapeutic interventions in space and time for Parkinson's disease.Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.Recent advances in RNA interference therapeutics for CNS diseases.Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model Transcriptional activity of novel ALDH1L1 promoters in the rat brain following AAV vector-mediated gene transfer Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis.A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease.Gene therapy for the neurological manifestations in lysosomal storage disorders.Advances in non-dopaminergic treatments for Parkinson's disease Preclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and from the pharmacology of analgesic drugs.Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.Gene therapy for Parkinson's disease: still a hot topic?Gene therapy research in Asia.Gene therapy for neurological disorders.Perspective on the Road toward Gene Therapy for Parkinson's Disease.Viral vectors for therapy of neurologic diseases.Preclinical study of rAAV2-sTRAIL: pharmaceutical efficacy, biodistribution and safety in animals.Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease.Neurotransmitter release: vacuolar ATPase V0 sector c-subunits in possible gene or cell therapies for Parkinson's, Alzheimer's, and psychiatric diseases.Adeno-Associated Virus-Based Gene Therapy for CNS Diseases.Therapies for Parkinson's diseases: alternatives to current pharmacological interventions.Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.Gene therapy approaches in the non-human primate model of Parkinson's disease.

P2860

Q26743393-8A03EF4B-4187-411A-8FB7-C8DC864B1CCF Q26801582-F360818A-4DF6-4473-B7DC-5C06838B7158 Q26824783-A10562B6-E0B0-4961-B6DC-DD33BCF5CA9A Q26826093-8099347D-C733-47DA-B4BB-5D50DE3D19EA Q26830610-9FB2FF09-21F3-4D72-BF99-A9ED2ECC768A Q26851325-633EDE95-F214-42F5-9296-BA542353DC5E Q26851517-8278530C-3191-4A0C-8B4C-339FCF076053 Q27024152-16C3AF19-892E-4B5C-A68F-2EF70F57390A Q27026177-EA531FFF-9FBA-4B8B-BBB2-C121B6DBAAF5 Q27310170-EE0C4B27-8798-4753-A8AE-B1723B71F3AD Q34762396-DEFAB91E-28E0-4120-9A8C-4D952BD32D9E Q35600310-F719502C-658B-49FC-A938-349610B6BF7D Q35899850-372155F1-2F4A-44F7-B96C-78A8E1BA589B Q36271585-2EB283AF-7A9B-4C11-8E92-E329801D674C Q36521756-C45A7990-205D-4FF9-A7F9-45FC5AE02A99 Q36569445-7B5F1EA2-83DB-4DD3-AFB0-C8DF832B8AE4 Q36745293-FC992F83-C5E3-47D1-83C2-036364BFA7F7 Q36925905-D714AFFD-B27B-4F4C-A251-B401E296FF3A Q36983193-081AC976-F7FA-427B-9322-E327AFCB4402 Q37069887-412DE31D-7D0E-4CD7-A03D-193A5CF2EC06 Q37458119-D1BBCD63-7EB2-4A4D-9B36-8C33D8AD4B82 Q37463967-53DA58D2-DFFA-4DE2-AFD0-788740B46863 Q38075068-DAE30EDC-1217-4B95-A09F-06166BCFEAC0 Q38112216-891394C7-92D3-47F2-932B-6A3E89BC4E84 Q38200599-E20E7062-A80B-4C70-A6BB-CCC48FB8B1EA Q38218083-B8A0B0A7-7E35-43F1-96A7-97F828A58D20 Q38245677-983EAAF7-CBD6-4A25-9979-5EE305ADDFBF Q38275513-FE5EF974-63BA-4AD5-9BA8-1955C37A1915 Q38284287-0A430743-689E-4B54-8182-AA022258EFF5 Q38654544-7DEB0C54-5FDB-4605-949A-5C050C77C675 Q38661071-13A753AA-26DB-418C-8777-003233290EE0 Q38719576-9C5596AD-A8FF-4DA6-B40C-8ED1222DBB5F Q38746238-BCE56B1F-6043-4681-8E6F-D1111A5B5B53 Q38827170-92BDE0C6-AC85-436B-9E70-C622B52D41E2 Q38839079-BA4093A7-5F2E-48C3-A1FA-E0016C76ED14 Q38854566-97A5FB13-92B0-4841-B5DB-AACDC6BCB72C Q38856794-CFB0C3C8-3D2C-4F92-93B3-B8498B1C273A Q38925121-DE4CD1FD-F579-4A02-ADF5-428B3B4C79EC Q38949089-F3A2D9E8-FD91-4CAA-A082-762D5C7CC358 Q39107176-0988B507-FBCD-44E5-BF22-3CA1F21673D1

P2860

Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease

http://www.wikidata.org/entity/Q35932749

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease

@ast

Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease

@en

type

label

Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease

@ast

Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease

@en

prefLabel

Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease

@ast

Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease

@en

P1433

Q35932749-C1EBB637-4CAE-404B-98B5-F21D1ABD56E4

P1476

Q35932749-F26A5E8A-C9B8-4F7A-985E-850DED2E1579

P2093

Q35932749-01F61099-D85E-435F-BA01-531FC573E635

Q35932749-3C1C9319-E459-4C60-B36B-3445BF2D8D9D

Q35932749-4F5063F7-A590-4CBE-8779-16CDB684CCCC

Q35932749-65B48EF3-8AC3-43DD-AFDB-B4B74A6E4C00

Q35932749-88F37686-436F-450F-998C-1533AF668D00

Q35932749-8EAB1C42-2540-4598-9275-4F17A539A72B

Q35932749-B56A087E-42ED-4C72-BB84-59D2BD627B06

Q35932749-D47E6440-D820-4F1C-8DAD-ED56B1C780E0

Q35932749-E068FB80-7E43-4B72-A559-D725B3DE0244

Q35932749-EC35762D-9EB4-4CE8-A813-E89EFEFFEC37

P2860

Q35932749-0E53F6BB-23C9-4B08-BA70-55444F7040FD

Q35932749-13A2911C-1796-4EB8-8B6B-C59BB7AA1334

Q35932749-298BB331-C035-4A43-988F-22DCACFEFD1F

Q35932749-2FB9988C-4845-4022-B22B-84A24FD08DEC

Q35932749-4682BECC-B960-4485-A656-952CE0371F0F

Q35932749-4B651D84-C397-437B-A695-A3F6D03D2FF3

Q35932749-5B63D5CF-9993-4901-854E-E9B0301E9E47

Q35932749-6F2B34E2-F802-4B03-B1F3-D45545113437

Q35932749-A83FB080-97E9-4BA0-A466-91A8ECBB9997

Q35932749-B58569CB-F3AB-40A3-B18A-D3739DCCEDCD

P304

Q35932749-70462F8B-0F01-44B5-A2B7-38116CD3EAA4

P31

Q35932749-7F8AB73F-E536-4BFC-8C79-944AC7A96C0D

P356

Q35932749-7BEB50D7-0CFB-4880-8E3A-B0BD2FFE782A

P433

Q35932749-591463EA-7D4E-4187-8B65-C4240D4C4A0F

P478

Q35932749-AD54307D-174C-445E-A5F6-7B80EAE3E673

P577

Q35932749-86E54102-415D-4641-9841-12F2544C6A27

P5875

Q35932749-07D6928E-A771-4C37-BA4E-3002164FE083

P698

Q35932749-B6684B26-B378-4B31-8EAE-76D7EC697916

P921

Q35932749-3C5F6884-CECB-4A6B-AFAE-CE8350745640

Q35932749-557BC4FA-E156-4398-8065-F85AB0551FBA

P932

Q35932749-09E2B090-6626-4FC0-AA2C-C044ACEBAA00

P356

P1433

Human Gene Therapy

P1476

Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease

@en

P2093

Chadwick W Christine

http://www.w3.org/2001/XMLSchema#string

Gabriele Mittermeyer

http://www.w3.org/2001/XMLSchema#string

John Forsayeth

http://www.w3.org/2001/XMLSchema#string

Kathryn H Rosenbluth

http://www.w3.org/2001/XMLSchema#string

Krystof S Bankiewicz

http://www.w3.org/2001/XMLSchema#string

Michael J Aminoff

http://www.w3.org/2001/XMLSchema#string

Paul L Kaplan

http://www.w3.org/2001/XMLSchema#string

Paul Larson

http://www.w3.org/2001/XMLSchema#string

Philip Starr

http://www.w3.org/2001/XMLSchema#string

Suzanne L Baker

http://www.w3.org/2001/XMLSchema#string

P2860

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects.

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

Subregional 6-[18F]fluoro-ʟ-m-tyrosine uptake in the striatum in Parkinson's disease.

The placebo effect in Parkinson's disease.

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease.

Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain.

Striatal volume differences between non-human and human primates

A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys.

Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain.

P304

377-381

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/HUM.2011.220

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221712607

http://www.w3.org/2001/XMLSchema#string

P698

22424171

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

4530392

http://www.w3.org/2001/XMLSchema#string